| You are here: Home: BCU 4|2004: Martine Piccart, MD, PhD: Select publications
Select pubilcations
Bendell JC et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97(12):2972-7. Abstract
Esteva FJ etal. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002 1;20(7):1800-8. Abstract
Extra JM etal. First-line trastuzumab (Herceptin R) plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC): results from a randomised phase II trial (M77001). Breast Cancer ResTreat 2003;82(Suppl):47; Abstract 217.
Lear-Kaul KC et al. Her-2/neu status in breast cancer metastases to the central nervous system. Arch Pathol Lab Med 2003;127(11):1451-7. Abstract
Leyland-Jones B et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every al. three weeks in combination with paclitaxel. J Clin Oncol 2003;21(21):3965-71. Abstract
Lindrud S et al. Central nervous system progression during systemic response to trastuzumab, humanized anti-HER-2/neu antibody, plus paclitaxel in a woman with refractory metastatic breast cancer. Breast J 2003;9(2):116-9. Abstract
Lower EE et al. Increased rate of brain metastasis with trastuzumab therapy not associated with impaired survival. Clin Breast Cancer 2003;4(2):114-9. Abstract
Montemurro Fetal. A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 2004;66(1):38-45.Abstract
Osoba D et al. Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002;20(14):3106-13. Abstract
Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000;18(11):2349-51. No abstract available
Robert N etal. Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive breast cancer. Breast CancerRes Treat 2002;76 (Suppl):37;Abstract 35.
Shmueli E et al. Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 2004;40(3):379-82. Abstract
Slamon DJ et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92. Abstract
Tedesco KL Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ al. overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: A multi-institutional phase II trial. J Clin Oncol 2004 5;22(6):1071-7. Abstract
Vogel CL et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20(3):719-26. Abstract
|
